


Applying Evidence to Individual Patients with Multimorbidity



Paul Glasziou,
Bond University, Australia



Evidence-informed medicine:

“Evidence-based medicine is the integration of best research evidence with clinical expertise and patient values”

- *Dave Sackett*



Patient Concerns



Clinical Expertise



Best Research

Overview



With Co-morbidities the principles of decision making the same but, more complex:

Overview



With Co-morbidities the principles of decision making the same but, more complex:

- Need to consider problem priorities
- Interactions (disease, drug) may alter
 - Prognosis, benefits or harms
 - Available data usually weaker

Clinical Decision in Comorbidity



- Understand circumstances, function, and goals of patient
- Assess patient/problem priorities
- Decision for individual problem


Clinical Decision in Comorbidity



- Understand circumstances, function, and goals of patient
- Assess patient/problem priorities
- **Decision for individual problem**

A general model for treatment decisions

- Higher risk patients (usually) have higher benefits
- Lower risk patients (usually) have lower benefits



1. Should Mr RM buy an electric toothbrush?

72 year old deaf pensioner

- Benign Prostatic Hypertrophy
- Parkinson's Disease
- gingivitis and frequent caries

Trials in young healthy people show improvements in gingivitis scores (but not caries).

Questions

1. Would the electric brush "work" for him?
2. What factors influence your & his decision?



1. Should Mr RM buy an electric toothbrush?

72 year old deaf pensioner

- ~~Benign Prostatic Hypertrophy~~
- Parkinson's Disease
- gingivitis and frequent caries

Trials in young healthy people show improvements in gingivitis scores (but not caries).

Questions

1. Would the electric brush "work" for him?
2. What factors influence your & his decision?



Electric toothbrushes

Are they effective?



Wiley InterScience home

Home | About Cochrane | Access to Cochrane | For Authors | Help | Save Title to My Profile

The Cochrane Library

Evidence for healthcare decision-making

BROWSE
Cochrane Reviews: [By Topic](#) | [New Reviews](#) | [Updated Reviews](#) | [A-Z](#) | [By Review Group](#)
Other Resources: [Other Reviews](#) | [Clinical Trials](#) | [Methods Studies](#) | [Technology Assessments](#) | [Economic Evaluations](#)

SEARCH
Enter search term
[Advanced Search](#) | [Me](#)

[More Info](#)

[Review] Manual versus powered toothbrushing for oral health

PDF (Size 522 K)

- [Abstract](#)
- [Plain language summary](#)
- [Background](#)
- [Objectives](#)
- [Criteria for considering studies for this review](#)
- [Search methods for identification of studies](#)
- [Methods of the review](#)
- [Description of studies](#)
- [Methodological quality](#)
- [Results](#)
- [Discussion](#)
- [Authors' conclusions](#)
- [Potential conflict of interest](#)
- [Acknowledgements](#)
- [Characteristics of included](#)

[Review] Manual versus powered toothbrushing for oral health

PG Robinson, SA Deacon, C Deery, M Heanue, AD Walmsley, HV Worthington, AM Glenny, WC Shaw

Cochrane Database of Systematic Reviews 2008 Issue 2 (Status: *Unchanged*)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DOI: 10.1002/14651858.CD002281.pub2 This version first published online: 20 April 2005 in Issue 2, 2005

This record should be cited as: Robinson PG, Deacon SA, Deery C, Heanue M, Walmsley AD, Worthington HV, Glenny AM, Shaw WC. Manual versus powered toothbrushing for oral health. *Cochrane Database of Systematic Reviews* 2005, Issue 2. Art. No.: CD002281. DOI: 10.1002/14651858.CD002281.pub2.

Abstract

Background

Remo
this.

Objec

To co

Search

We se
MED
contac

Yes – for university students
No patients with Parkinson's disease

brushing in achieving

verse effects and cost.

ssue 2, 2004);

Manufacturers were

Trials of toothbrushing in all diseases?

Diagnosis Pro (www.diagnosispro.com)

- 13,000 diseases;



The screenshot shows the top section of the Orphanet website. At the top right, there is a language selection menu with options for Français, English (highlighted), Español, Deutsch, and Italiano. Below this, the Orphanet logo is displayed on the left, accompanied by logos for Inserm, the French flag, and the European Union. To the right of the logo, the text reads "The portal for rare diseases and orphan drugs". Further right, there are links for "Homepage", "Help", and "Contact us". At the bottom of the header, a dark blue navigation bar contains eight menu items: "Rare diseases", "Orphan drugs", "Clinics", "Diagnostic tests", "Research and trials", "Patient organisations", "Directory of resources", and "Other information".

How many rare diseases are there ?


There are thousands of rare diseases. To date, six to seven thousand rare diseases have been found and approximately five new diseases are described every week in the medical literature. This number also depends upon the accuracy of the

Should Mr RM buy an electric toothbrush? Option 1: new evidence

Do an n-of-1 trial?


Left side: Electric

Right side: Normal



Should Mr RM buy an electric toothbrush?

Option 2: reasonable extrapolation



2. Are statins worthwhile for this patient with a history of TIA?

81 year old male with:

1. **Transient ischemic attacks (TIA)**
2. Non-H.pylori ulcers & Severe GERD
3. NSAID intolerance
4. Chronic neck pain

- CT scan shows small infarcts
- Cholesterol "normal" 5.8mmol/l

Should he be taking a statin?



TIA treatments and interaction with co-morbidities

		TIA treatments	
	Low-dose Aspirin	BP-lowering	Statin
Neck OA	NSAID	-	-
GERD	-	-	-
Ulcers	Intolerant; Use clopidogrel	-	-

Do “statins” work in those with a history (Hx) of stroke?

Subgroup Analysis




Figure 3. Effect of pravastatin on total stroke (fatal or nonfatal) according to baseline characteristic (95% CIs around hazard

(*Circulation*. 2001;103:387-392.)

How does predicted risk change the benefit?

<i>Baseline Risk</i>	<i>Relative Risk Reduction</i>	<i>Absolute Risk Reduction</i>	<i>Number needed to Treat</i>
8%	25%	2%	50

← Trial patients


How does predicted risk change the benefit?

<i>Baseline Risk</i>	<i>Relative Risk Reduction</i>	<i>Absolute Risk Reduction</i>	<i>Number needed to Treat</i>	
20%	25%			← High risk patient
8%	25%			← Trial patients
4%	25%			← Typical patients
1%	25%			← Low risk patient

↑ For biological effect & transferability

↑ For clinical decision making

2. Are statins worthwhile for this patient with a history of TIA?



3. Fractured hip and carotid stenosis


- A 92 year old man with bilateral carotid stenosis fell and fractured his hip.
- The fracture needs a hip replacement but the carotid stenosis puts him at high risk.
- *What should be done?*



(benefit same; increased harm;
patient's priorities crucial)

Summary: Steps from trials to individual decisions

1. What are the benefits and harms?
2. How do co-morbidities change the benefits or the harms?
3. Is the predicted net benefit a worthwhile priority?



Take home messages



With Co-morbidities the principles of decision making the same but, more complex:

- Need to consider problem priorities
- Interactions (disease, drug) may alter
 - Prognosis, benefits or harms
 - Available data usually weaker